AU2010278645A1 - Compositions and methods for treating Parkinson's disease - Google Patents

Compositions and methods for treating Parkinson's disease Download PDF

Info

Publication number
AU2010278645A1
AU2010278645A1 AU2010278645A AU2010278645A AU2010278645A1 AU 2010278645 A1 AU2010278645 A1 AU 2010278645A1 AU 2010278645 A AU2010278645 A AU 2010278645A AU 2010278645 A AU2010278645 A AU 2010278645A AU 2010278645 A1 AU2010278645 A1 AU 2010278645A1
Authority
AU
Australia
Prior art keywords
dopamine
days
receptor
parkinson
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010278645A
Other languages
English (en)
Inventor
Philip Seeman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clera Inc
Original Assignee
Clera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clera Inc filed Critical Clera Inc
Publication of AU2010278645A1 publication Critical patent/AU2010278645A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010278645A 2009-07-31 2010-07-30 Compositions and methods for treating Parkinson's disease Abandoned AU2010278645A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23026409P 2009-07-31 2009-07-31
US61/230,264 2009-07-31
PCT/CA2010/001185 WO2011011886A1 (en) 2009-07-31 2010-07-30 Compositions and methods for treating parkinson's disease

Publications (1)

Publication Number Publication Date
AU2010278645A1 true AU2010278645A1 (en) 2012-03-08

Family

ID=43528672

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010278645A Abandoned AU2010278645A1 (en) 2009-07-31 2010-07-30 Compositions and methods for treating Parkinson's disease

Country Status (12)

Country Link
US (1) US9192605B2 (enExample)
EP (1) EP2459194A4 (enExample)
JP (1) JP5756105B2 (enExample)
KR (1) KR20120103557A (enExample)
CN (1) CN102548555A (enExample)
AU (1) AU2010278645A1 (enExample)
BR (1) BR112012008193A2 (enExample)
CA (1) CA2769149A1 (enExample)
IL (1) IL217149A0 (enExample)
MX (1) MX2012001290A (enExample)
NZ (1) NZ598247A (enExample)
WO (1) WO2011011886A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2893427C (en) * 2012-12-24 2023-01-10 Neurogastrx, Inc. Methods for treating gi tract disorders
JP6371716B2 (ja) * 2014-04-01 2018-08-08 東京エレクトロン株式会社 基板液処理装置及び基板液処理方法並びに基板液処理プログラムを記録したコンピュータ読み取り可能な記録媒体
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
CN114601928B (zh) * 2022-04-02 2023-03-17 首都医科大学 一种钙超载介导神经元死亡的标志物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
RU2057529C1 (ru) * 1994-05-30 1996-04-10 Алексей Михайлович Коршунов Способ лечения синдрома паркинсонизма
US20010056101A1 (en) * 1998-06-29 2001-12-27 Carol A. Tamminga Use of dopamine receptor antagonists in combination with partial dopamine agonist to prevent tolerance in treating nervous disorders related to dopamine dysfunction
DE10111486A1 (de) * 2001-03-09 2002-10-02 Ralph R Dawirs Verwendung einer oder mehrerer neuroaktiver Substanzen zur Behandlung der Parkinsonschen Krankheit
PT1539135E (pt) * 2002-09-17 2007-07-12 Motac Neuroscience Ltd Tratamento da discinesia.
JP2006505589A (ja) * 2002-10-22 2006-02-16 ドラッグアビューズ サイエンシズ エス．アー．エス． 選択的ドーパミンｄ１受容体アゴニストを使用した認知障害の治療法
CA2628298A1 (en) * 2004-11-03 2006-05-11 Clera Inc. Method to detect dopamine receptors in the functional d2high state
NZ586963A (en) 2008-02-05 2012-11-30 Clera Inc Use of dopamine d2 receptor inhibitors for alleviating depression or improving cognition

Also Published As

Publication number Publication date
BR112012008193A2 (pt) 2016-03-01
CN102548555A (zh) 2012-07-04
MX2012001290A (es) 2012-06-12
WO2011011886A1 (en) 2011-02-03
JP2013500943A (ja) 2013-01-10
US9192605B2 (en) 2015-11-24
US20120115910A1 (en) 2012-05-10
EP2459194A4 (en) 2012-12-19
EP2459194A1 (en) 2012-06-06
CA2769149A1 (en) 2011-02-03
NZ598247A (en) 2014-01-31
JP5756105B2 (ja) 2015-07-29
KR20120103557A (ko) 2012-09-19
IL217149A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
CN1255854A (zh) 1,2,4－三唑并[1,5－c]嘧啶杂环类似物在制备用于治疗心血管疾病的药物中的用途
JP6977024B2 (ja) ５−ｈｔ２ｃ受容体アゴニストおよび組成物ならびに使用方法
KR101630467B1 (ko) 진통 내성 억제제
TW200829244A (en) Therapeutic combinations 482
CN101310724A (zh) 腺苷A2a受体拮抗剂的应用
JP2018519251A (ja) ５−ｈｔ２ｃ受容体アゴニストおよび組成物ならびに使用方法
WO2001013909A2 (en) Compositions and methods for treating opiate intolerance
US9192605B2 (en) Compositions and methods for treating parkinson's disease
US12291528B2 (en) Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
CA2795038C (en) Opioid receptor antagonist (naltrexone) for use in treating herpes zoster disease
CZ295801B6 (cs) Antitusické přípravky
KR101477043B1 (ko) 디스키네시아의 치료 또는 예방제
JP2003511410A (ja) 肥満症の治療のためのモルホリノール誘導体
CA2672273C (en) Methods for the treatment of alcohol abuse, addiction and dependency
CN101778632B (zh) 综合失调症的治疗或预防药
HK1172275A (en) Compositions and methods for treating parkinson's disease
WO2010074607A2 (ru) Действующее вещество и фармацевтическая композиция для лечения алкогольной зависимости, способ получения и применения
RU2761219C2 (ru) Терапевтическое средство от расстройств, связанных с употреблением алкоголя
WO2018178262A1 (en) Dihydrotetrabenazine for the treatment of anxiety and psychoses
HK40010293B (en) 5-ht2c receptor agonists and compositions and methods of use
HK40010293A (en) 5-ht2c receptor agonists and compositions and methods of use
ITMI990815A1 (it) Derivati morfinoidi procedimento per la loro preparzione e loro impiego terapeutico
JPWO2002010167A1 (ja) ２−アリール−８−オキソジヒドロプリン誘導体を有効成分とする痴呆症治療剤

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application